Research on Tenofovir (Viread)
HIV Treatment Research
- Serious Non-AIDS Health Problems (Especially Heart Problems) Appear Less Likely With Truvada Than Epzicom, But Low Bone Mineral Density Is More Likely, Switch Study Finds (October 20, 2009)
In Clinical Infectious Diseases
- A Large Study Looks at Tenofovir and Kidney Health (July/August 2009)
To read PDF, click here
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- Age, Tenofovir and the Kidneys (July/August 2009)
To read PDF, click here
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- Gilead Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV (April 17, 2009)
Study will assess safety and efficacy of single-tablet regimen containing elvitegravir boosted by GS 9350 and Truvada compared to Atripla.
From Gilead Sciences, Inc.
- Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Topical PrEP Comparison: Tenofovir Alone May Be as Effective as Tenofovir/FTC, Study Finds (February 9, 2009)
Walid Heneine, Ph.D., explains the results of a study in macaques which found that a topical gel offered complete protection against SIV infection -- regardless of whether that gel contained tenofovir alone or tenofovir in combination with emtricitabine.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Combining Sustiva + Viread May Increase Liver Risk, Case Reports Suggest (May 9, 2008)
In aidsmap.com
- Tenofovir Shows Excellent Promise as a Treatment for Hepatitis B Monoinfection (April 25, 2008)
From aidsmap.com
- Major Study Finds Red Flags When Using Epzicom as First-Line Therapy in People With High Viral Load (February 28, 2008)
Combination therapy that includes ABC/3TC found less effective in subgroup of antiretroviral-naive individuals.
From U.S. National Institute of Allergy and Infectious Diseases
- Tenofovir Appears Effective Against HIV and Hepatitis B in Coinfected People (June 12, 2007)
From aidsmap.com
- Link Between Tenofovir and Renal Toxicity Remains Tenuous, but Monitoring Is Warranted (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- HIV JournalView: Risk of Tenofovir Nephrotoxicity May Be Real, Though Murky (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- HIV JournalView: Tenofovir + Didanosine: The Downfall of a Lovely Combination (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration
|
|
Advertisement
|
E-Mail
Glossary
Share
